Last Price$488.3(2.3%)
Market Cap$124.8B
LTM Operating Expenses
$9,722.1M
YoY Growth
+126.3%
3Y CAGR
+35.7%
5Y CAGR
+32.1%
Stock quality & Intrinsic value
6/10
61.6% overvalued
Vertex Pharmaceuticals Incorporated Operating Expenses
Annual
Quarterly
LTM
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | $292.5M | $429.6M | $597.8M | $618.2M | $680.0M | $825.2M | $1,108.4M | $1,243.0M | $1,281.1M | $1,160.9M | $1,373.3M | $1,480.5M | $1,820.7M | $1,974.1M | $2,413.0M | $2,600.0M | $3,891.2M | $3,485.0M | $4,775.0M | $9,722.5M |
Overvalued or undervalued?
Check the intrinsic value for VRTX
and see if it's the right time to invest.
Vertex Pharmaceuticals Incorporated (VRTX) Operating Expenses comparison analysis
General
LTM Operating Expenses
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
Vertex Pharmaceuticals IncorporatedVRTX
$9,722.1M
126.3%
35.7%
32.1%
Median Peer Set
$2,200.0M
36.3%
19.6%
16.0%
Regeneron Pharmaceuticals, Inc.REGN
$7,975.0M
12.8%
19.4%
10.4%
Incyte CorporationINCY
$3,851.0M
38.0%
19.9%
18.9%
BioNTech SEBNTX
$3,812.4M
201.8%
103.8%
137.9%
BeiGene, Ltd.BGNE
$3,650.0M
95.0%
59.9%
62.8%
argenx SEARGX
$2,298.2M
76.8%
272.5%
61.5%
Alnylam Pharmaceuticals, Inc.ALNY
$2,101.8M
16.8%
14.2%
13.1%
BioMarin Pharmaceutical Inc.BMRN
$1,781.1M
4.5%
6.9%
3.9%
United Therapeutics CorporationUTHR
$1,190.7M
34.5%
5.7%
(4.8%)
Royalty Pharma plcRPRX
$971.0M
12.6%
4.2%
N/A
Summit Therapeutics Inc.SMMT
$211.1M
137.1%
33.9%
46.8%
VRTX key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 160.9 56.6% | 216.4 34.5% | 199.0 (8.0%) | 175.5 (11.8%) | 102.0 (41.9%) | 143.4 40.5% | 1,410.6 883.9% | 1,527.0 8.3% | 1,212.0 (20.6%) | 580.4 (52.1%) | 1,032.3 77.9% | 1,702.2 64.9% | 2,488.7 46.2% | 3,047.6 22.5% | 4,162.8 36.6% | 6,205.7 49.1% | 7,574.4 22.1% | 8,930.7 17.9% | 9,869.2 10.5% | 11,020.1 11.7% |
| Cost of Goods Sold (COGS) | 10.1 | 12.2 | 13.9 | 15.7 | 14.2 | 12.7 | 80.5 | 279.9 | 130.3 | 61.0 | 125.5 | 210.5 | 275.1 | 409.5 | 547.8 | 736.3 | 904.2 | 1,080.3 | 1,262.2 | 1,530.5 |
% margin | 150.8 93.7% | 204.2 94.4% | 185.1 93.0% | 159.8 91.1% | 87.8 86.1% | 130.6 91.1% | 1,330.1 94.3% | 1,247.2 81.7% | 1,081.7 89.3% | 519.4 89.5% | 906.8 87.8% | 1,491.7 87.6% | 2,213.5 88.9% | 2,638.1 86.6% | 3,615.1 86.8% | 5,469.4 88.1% | 6,670.2 88.1% | 7,850.4 87.9% | 8,607.0 87.2% | 9,489.6 86.1% |
| Operating Expenses | 292.5 | 429.6 | 597.8 | 618.2 | 680.0 | 825.2 | 1,108.4 | 1,243.0 | 1,281.1 | 1,160.9 | 1,373.3 | 1,480.5 | 1,820.7 | 1,974.1 | 2,413.0 | 2,600.0 | 3,891.2 | 3,485.0 | 4,775.0 | 9,722.5 |
| Research & Development Expenses (R&D) | 248.5 | 371.7 | 513.1 | 516.3 | 550.7 | 637.4 | 707.7 | 806.2 | 918.8 | 855.5 | 996.2 | 1,047.7 | 1,324.6 | 1,416.5 | 1,754.5 | 1,829.5 | 3,051.1 | 2,540.3 | 3,162.9 | 3,630.3 |
| Selling, General & Administrative Expenses (SG&A) | 44.0 | 57.9 | 84.7 | 101.9 | 129.3 | 187.8 | 400.7 | 436.8 | 362.3 | 305.4 | 377.1 | 432.8 | 496.1 | 557.6 | 658.5 | 770.5 | 840.1 | 944.7 | 1,136.6 | 1,464.3 |
% margin | (149.9) (93.2%) | (229.0) (105.9%) | (419.8) (210.9%) | (462.7) (263.6%) | (613.4) (601.1%) | (696.1) (485.5%) | 113.8 8.1% | 2.3 0.2% | (903.4) (74.5%) | (692.4) (119.3%) | (468.7) (45.4%) | 9.9 0.6% | 123.2 5.0% | 635.2 20.8% | 1,197.6 28.8% | 2,856.3 46.0% | 2,782.1 36.7% | 4,307.4 48.2% | 4,307.5 43.6% | (232.9) (2.1%) |
| Interest Income | 0.0 | 0.0 | 0.0 | 16.3 | 5.0 | 2.0 | 1.9 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 11.7 | 0.0 | 63.7 | 22.2 | 4.9 | 144.6 | 614.7 | 598.1 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 13.5 | 13.2 | 19.3 | 36.6 | 14.7 | 22.7 | 72.9 | 84.2 | 81.4 | 57.6 | 34.1 | 58.5 | 58.2 | 61.5 | 54.8 | 44.1 | 30.6 |
| Pre-tax Income | (173.4) | (206.9) | (426.9) | (464.2) | (642.2) | (754.6) | 60.4 | (12.4) | (976.1) | (734.9) | (559.6) | (67.4) | (15.7) | 600.2 | 1,394.9 | 3,116.8 | 2,730.4 | 4,232.4 | 4,379.8 | 248.5 |
% effective tax rate | 61.7 (35.6%) | (18.5) 8.9% | (21.4) 5.0% | (30.7) 6.6% | 19.3 (3.0%) | 19.3 (2.6%) | 19.3 31.9% | 38.8 (313.0%) | (288.6) 29.6% | 7.0 (0.9%) | 30.4 (5.4%) | 16.7 (24.7%) | (107.3) 684.1% | (1,486.9) (247.7%) | 218.1 15.6% | 405.2 13.0% | 388.3 14.2% | 910.4 21.5% | 760.2 17.4% | 784.1 315.5% |
% margin | (203.4) (126.4%) | (206.9) (95.6%) | (391.3) (196.6%) | (459.9) (262.0%) | (641.6) (628.7%) | (754.6) (526.3%) | 29.6 2.1% | (107.0) (7.0%) | (445.0) (36.7%) | (738.6) (127.2%) | (558.1) (54.1%) | (112.1) (6.6%) | 263.5 10.6% | 2,096.9 68.8% | 1,176.8 28.3% | 2,711.7 43.7% | 2,342.1 30.9% | 3,322.0 37.2% | 3,619.6 36.7% | (535.6) (4.9%) |
| EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.32) | (0.46) | 1.06 | 8.25 | 4.58 | 10.44 | 9.09 | 12.97 | 14.05 | (2.08) |
| Diluted EPS | (2.28) | (1.83) | (3.03) | (3.27) | (3.70) | (3.77) | 0.14 | (0.50) | (1.98) | (3.14) | (2.31) | (0.46) | 1.04 | 8.09 | 4.51 | 10.29 | 9.01 | 12.82 | 13.89 | (2.08) |
% margin | (114.4) (71.1%) | (199.5) (92.2%) | (385.2) (193.6%) | (426.2) (242.8%) | (598.9) (586.9%) | (704.9) (491.7%) | 133.9 9.5% | 42.5 2.8% | (554.8) (45.8%) | (598.8) (103.2%) | (411.3) (39.8%) | 75.5 4.4% | 103.3 4.1% | 706.8 23.2% | 1,560.4 37.5% | 3,284.5 52.9% | 2,917.5 38.5% | 4,435.5 49.7% | 4,605.2 46.7% | 486.3 4.4% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Vertex Pharmaceuticals Incorporated's Operating Expenses?
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Operating Expenses is $9,722.1M, based on the financial report for Dec 31, 2024 (Q4’2024).
2) What is Vertex Pharmaceuticals Incorporated's Operating Expenses growth rate?
Over the last year, Vertex Pharmaceuticals Incorporated's Operating Expenses growth was 126.3%. The average annual Operating Expenses growth rates for Vertex Pharmaceuticals Incorporated have been 39.2% over the past three years, 32.1% over the past five years.
3) Is Vertex Pharmaceuticals Incorporated's Operating Expenses growth rate Good?
Over the last year, Vertex Pharmaceuticals Incorporated's Operating Expenses growth was 126.3%, which is higher than industry growth of 0.1%. It indicates that Vertex Pharmaceuticals Incorporated's Operating Expenses growth is Bad.